Ambrose Emmanuela E, Makani Julie, Chami Neema, Masoza Tulla, Kabyemera Rogatus, Peck Robert N, Kamugisha Erasmus, Manjurano Alphaxard, Kayange Neema, Smart Luke R
Department of Paediatrics and Child Health, Catholic University of Health & Allied Sciences and Bugando Medical Centre, Mwanza, Tanzania.
Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26735. Epub 2017 Aug 2.
Worldwide, hemoglobinopathies affect millions of children. Identification of hemoglobin disorders in most sub-Saharan African countries is delayed until clinical signs of the disease are present. Limited studies have been conducted to understand their prevalence and clinical presentation among newborns in resource-limited settings.
This was a prospective cohort study. Newborns (aged 0-7 days) at two hospitals in Northwestern Tanzania were enrolled and followed prospectively for 6 months. Clinical and laboratory information were collected at baseline. Participants were screened for hemoglobinopathies using high-performance liquid chromatography. Clinical and laboratory follow-up was performed at 3 and 6 months for those with hemoglobinopathies as well as a comparison group of participants without hemoglobinopathies.
A total of 919 newborns were enrolled. Among these, 1.4% (13/919) had sickle cell anemia or Hb S/β -thalassemia (Hb FS), and 19.7% (181/919) had sickle cell trait or Hb S/β thalassemia (Hb FAS). Furthermore, 0.2% (two of 919) had β -thalassemia. Red cell indices compared between Hb FS, Hb FAS, and Hb FA were similar at baseline, but hemoglobin was lower and red cell distribution width was higher in children with Hb FS at 3- and 6-month follow-up. Febrile episodes were more common for children with Hb FS at 3- and 6-month follow-up.
The prevalence of sickle cell disease among neonates born in Northwestern Tanzania is one of the highest in the world. Newborn screening is needed early in life to identify neonates with hemoglobinopathies so that clinical management may commence and morbidity and mortality related to hemoglobinopathies be reduced.
在全球范围内,血红蛋白病影响着数百万儿童。在大多数撒哈拉以南非洲国家,血红蛋白疾病的诊断会延迟到出现疾病的临床症状时。针对资源有限地区新生儿中这些疾病的患病率及临床表现的研究较少。
这是一项前瞻性队列研究。在坦桑尼亚西北部的两家医院招募了0至7天的新生儿,并对其进行了为期6个月的前瞻性随访。在基线时收集临床和实验室信息。使用高效液相色谱法对参与者进行血红蛋白病筛查。对患有血红蛋白病的参与者以及未患血红蛋白病的对照组参与者在3个月和6个月时进行临床和实验室随访。
共招募了919名新生儿。其中,1.4%(13/919)患有镰状细胞贫血或血红蛋白S/β地中海贫血(血红蛋白FS),19.7%(181/919)患有镰状细胞性状或血红蛋白S/β地中海贫血(血红蛋白FAS)。此外,0.2%(919名中的2名)患有β地中海贫血。血红蛋白FS、血红蛋白FAS和血红蛋白FA在基线时的红细胞指数相似,但在3个月和6个月随访时,血红蛋白FS患儿的血红蛋白较低,红细胞分布宽度较高。在3个月和6个月随访时,血红蛋白FS患儿发热发作更为常见。
坦桑尼亚西北部出生的新生儿中镰状细胞病的患病率是世界上最高的之一。需要在生命早期进行新生儿筛查,以识别患有血红蛋白病的新生儿,从而开始临床管理并降低与血红蛋白病相关的发病率和死亡率。